ABMD - Abiomed, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
259.14
+2.99 (+1.17%)
As of 1:14PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close256.15
Open258.12
Bid259.75 x 800
Ask260.27 x 800
Day's Range257.00 - 262.63
52 Week Range228.00 - 459.75
Volume231,112
Avg. Volume817,040
Market Cap11.694B
Beta (3Y Monthly)1.16
PE Ratio (TTM)46.19
EPS (TTM)5.61
Earnings DateJul 24, 2019 - Jul 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est336.88
Trade prices are not sourced from all markets
  • IART vs. ABMD: Which Stock Should Value Investors Buy Now?
    Zacks4 hours ago

    IART vs. ABMD: Which Stock Should Value Investors Buy Now?

    IART vs. ABMD: Which Stock Is the Better Value Option?

  • Impella Featured as an Innovative Technology at U.S. Capitol Event Showcasing Improvements to Women’s Health
    Business Wire5 days ago

    Impella Featured as an Innovative Technology at U.S. Capitol Event Showcasing Improvements to Women’s Health

    Abiomed’s (ABMD) Impella platform is being featured today at a Washington, D.C., event showcasing innovations in medical technology that improve healthcare for women. Abiomed’s participation supports its Women’s Initiative for Heart Recovery, which provides education and raises awareness of women’s cardiovascular diseases and the opportunity for heart recovery. One young woman who benefited from heart recovery with Impella support is Iman Dorty, who is speaking at today’s event.

  • Hedge Funds Have Never Been This Bullish On ABIOMED, Inc. (ABMD)
    Insider Monkey5 days ago

    Hedge Funds Have Never Been This Bullish On ABIOMED, Inc. (ABMD)

    The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]

  • Markit8 days ago

    See what the IHS Markit Score report has to say about Abiomed Inc.

    Abiomed Inc NASDAQ/NGS:ABMDView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for ABMD with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ABMD totaled $7.94 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Abiomed, Inc. (NASDAQ:ABMD): Will The Growth Last?
    Simply Wall St.11 days ago

    Abiomed, Inc. (NASDAQ:ABMD): Will The Growth Last?

    Abiomed, Inc.'s (NASDAQ:ABMD) latest earnings announcement in March 2019 showed that the business benefited from a...

  • Speedy Medtech: Why These Fast-Growing Stocks Should Be On Your Radar
    Investor's Business Daily12 days ago

    Speedy Medtech: Why These Fast-Growing Stocks Should Be On Your Radar

    Medical technology stocks hit record highs last year and are rising thus far in 2019. Two of the fastest growing among them have tacked on double-digit earnings growth for several years.

  • New Strong Sell Stocks for June 5th
    Zacks13 days ago

    New Strong Sell Stocks for June 5th

    Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.

  • Not Just Uber: 5 Stocks Analysts Love Unanimously
    Investor's Business Daily14 days ago

    Not Just Uber: 5 Stocks Analysts Love Unanimously

    Uber shares are popping today on word analysts practically all love the stock. But turns out, it's not the only stock showered with "buy" ratings from analysts. The question, though, is whether that should matter to investors.

  • Why Is Abiomed (ABMD) Up 0.6% Since Last Earnings Report?
    Zacks17 days ago

    Why Is Abiomed (ABMD) Up 0.6% Since Last Earnings Report?

    Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Abiomed (ABMD) Dips More Than Broader Markets: What You Should Know
    Zacks18 days ago

    Abiomed (ABMD) Dips More Than Broader Markets: What You Should Know

    Abiomed (ABMD) closed the most recent trading day at $261.92, moving -1.68% from the previous trading session.

  • Business Wire20 days ago

    Abiomed to Present at Upcoming Investor Conferences

    Abiomed, Inc. , a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer

  • GuruFocus.com26 days ago

    Abiomed Inc (ABMD) Files 10-K for the Fiscal Year Ended on March 31, 2019

    Abiomed Inc (NASDAQ:ABMD) files its latest 10-K with SEC for the fiscal year ended on March 31, 2019.

  • ABIOMED Gets FDA Confirmation of the Safety of Impella RP
    Zacks27 days ago

    ABIOMED Gets FDA Confirmation of the Safety of Impella RP

    ABIOMED (ABMD) receives the FDA confirmation of the safety and effectiveness of the company's Impella RP heart pump.

  • FDA clears Abiomed heart pump after concerns over death rate
    American City Business Journals27 days ago

    FDA clears Abiomed heart pump after concerns over death rate

    Months after federal regulators warned doctors that one of the heart pumps made by Danvers’ Abiomed could be linked to a higher rate of death than previously thought, the company’s device has been cleared by the FDA.

  • Top 5 S&P 500 Stocks for 2018 by Performance
    Investopedia28 days ago

    Top 5 S&P 500 Stocks for 2018 by Performance

    The Standard & Poor's 500 index—commonly called the S&P 500, or simply the S&P—is the primary gauge of the large-cap U.S. equities market. It is based on the market capitalization figures of the top 500 companies that list their common stock on the NYSE or NASDAQ. Based on available historical data, the S&P has generated an average annual return of around 9.8% from 1928 through 2016.

  • Business Wire28 days ago

    FDA Confirms Impella RP is Safe and Effective; Only Right-Sided Device with FDA Approval

    Use of early identification protocol leads to higher survival and native heart recovery, as demonstrated in FDA studies

  • National Cardiogenic Shock Initiative (NCSI) with Impella Best Practices Demonstrates 72% Survival with 98% Native Heart Recovery
    Business Wire28 days ago

    National Cardiogenic Shock Initiative (NCSI) with Impella Best Practices Demonstrates 72% Survival with 98% Native Heart Recovery

    Improves upon AMI cardiogenic shock historical survival of 50%

  • ABIOMED (ABMD) to Launch Impella CP With SmartAssist at SCAI
    Zacks29 days ago

    ABIOMED (ABMD) to Launch Impella CP With SmartAssist at SCAI

    ABIOMED's (ABMD) Impella CP receives Japanese PMDA approval in recent times.

  • Top 5 Health Care Stocks of 2018 by Performance
    Investopedialast month

    Top 5 Health Care Stocks of 2018 by Performance

    The healthcare sector performed well in 2018, driven by positive growth in sub-segments such as medical devices, health insurance, hospitals, nursing homes, and pharmaceuticals, which offset losses in biomedical and genetics, home healthcare, medical, and dental supplies. Moving ahead into 2019, as the decade-long expansion faces a period of heightened volatility and risk, the health care sector should benefit from a shift towards more defensive sectors. In a recent sector roundup from Charles Schwab, the firm rated health care at "outperform," citing the group’s strong balance sheets, attractive dividend yields, and improved cost structure.

  • Impella SmartAssist Platform Launches at SCAI, Designed to Further Improve Patient Outcomes
    Business Wirelast month

    Impella SmartAssist Platform Launches at SCAI, Designed to Further Improve Patient Outcomes

    Abiomed  announces today that the Impella CP with SmartAssist, which is designed to improve patient outcomes with advanced algorithms and simplified patient management, will be commercially available beginning at the 2019 Society for Cardiovascular Angiography & Interventions Scientific Sessions through a controlled launch process at select sites.

  • ABIOMED's Impella 5.0 and LD Receive Expanded FDA Approvals
    Zackslast month

    ABIOMED's Impella 5.0 and LD Receive Expanded FDA Approvals

    ABIOMED's (ABMD) FDA-approved Impella 2.5 and Impella CP treat certain advanced heart failure patients.

  • FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy
    Business Wirelast month

    FDA Approves Impella 5.0 and Impella LD Extended Duration of Use to 14 Days for Cardiogenic Shock Derived from AMI or Cardiomyopathy

    Abiomed (ABMD) announces the U.S. FDA has approved the expansion of the Impella 5.0 and Impella LD PMA labeling for the treatment of cardiogenic shock. The Impella 5.0 and the Impella LD are forward flow heart pumps that deliver up to 5 L/min, stabilizing a patient’s hemodynamics, unloading the left ventricle, and perfusing the end organs, allowing for the potential of native heart recovery or return to heart function baseline. The Impella 5.0 is implanted through the femoral or axillary artery and the Impella LD is implanted directly into the aorta.

  • Is ABIOMED, Inc.'s (NASDAQ:ABMD) High P/E Ratio A Problem For Investors?
    Simply Wall St.last month

    Is ABIOMED, Inc.'s (NASDAQ:ABMD) High P/E Ratio A Problem For Investors?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...

  • Motley Foollast month

    Abiomed and Intersect ENT Stumble to Start 2019

    These two med-tech companies failed to impress investors in the first quarter. Is the bull case for owning these stocks still intact?

  • ShockWave Medical's Revenue Soars in Its Public Debut
    Motley Foollast month

    ShockWave Medical's Revenue Soars in Its Public Debut

    The medical device maker's first earnings report as a public company featured explosive revenue growth and upbeat full-year guidance.